DexCom (DXCM) Tops Q2 EPS by 44c, Revenues Beat; Offers FY20 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
DexCom (DXCM) PT Raised to $540 at Cowen
July 24, 2020 8:07 AM EDTCowen analyst Doug Schenkel raised the price target on DexCom (NASDAQ: DXCM) to $540.00 (from $450.00) while maintaining an Outperform rating.
The analyst commented, "UnitedHealthcare recently announced the launch of its Level2 program for Type 2 diabetes management. All participants are required to wear a DXCM... More



